The management of the central nervous system (CNS) disorders is challenging, due to the
need of drugs to cross the blood‒brain barrier (BBB) and reach the brain. Among the …

Nose-to-brain drug delivery has been of great interest for the treatment of many central
nervous system (CNS) diseases and psychiatric disorders over past decades. Several …

The interest in extracellular vesicles (EVs) increased during the last decade. It is now
established that these vesicles play a role in the pathogenesis of central nervous system …

Alzheimer's disease (AD) is a devastating disease of the aging population characterized by
the progressive and slow brain decay due to the formation of extracellular plaques in the …

The research was aimed to formulate the Donepezil (DPZ)-loaded nanostructured lipid
carriers (NLCs) and coated with chitosan (CH) for brain targeting through the intranasal …

Abstract Dexibuprofen (DBPN), a non-steroidal anti-inflammatory drug (NSAID), exhibit its
action by inhibiting COX enzymes. It belongs to BCS class Ⅱ drugs, owing to its poor …

Neurodegenerative disorders are distinguished by the gradual deterioration of the nervous
system's structure and function due to oxidative stress, mitochondrial dysfunction, protein …

Neurodegenerative disorders including Alzheimer's, Parkinson's, and dementia are chronic
and advanced diseases that are associated with loss of neurons and other related …

The strategies to avoid blood brain barrier are been explored to improve brain targeting
therapeutics in order to ensure potential prospects of nose to brain delivery. In this research …

Since health care systems dedicate substantial resources to Alzheimer's disease (AD), it
poses an increasing challenge to scientists and health care providers worldwide, especially …